SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 267 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $798,000 | -14.9% | 33,650 | -1.5% | 0.07% | -14.1% |
Q3 2019 | $938,000 | -17.0% | 34,150 | 0.0% | 0.08% | -15.0% |
Q2 2019 | $1,130,000 | -8.3% | 34,150 | -2.8% | 0.10% | -7.4% |
Q1 2019 | $1,232,000 | -1.2% | 35,150 | -6.4% | 0.11% | -12.2% |
Q4 2018 | $1,247,000 | -33.7% | 37,550 | +0.5% | 0.12% | -18.0% |
Q3 2018 | $1,881,000 | -15.8% | 37,350 | 0.0% | 0.15% | -20.6% |
Q2 2018 | $2,235,000 | +18.3% | 37,350 | -9.5% | 0.19% | +27.7% |
Q1 2018 | $1,889,000 | +10.9% | 41,250 | -3.5% | 0.15% | +16.5% |
Q4 2017 | $1,704,000 | -0.4% | 42,750 | 0.0% | 0.13% | -4.5% |
Q3 2017 | $1,710,000 | -5.6% | 42,750 | +1.7% | 0.13% | -8.3% |
Q2 2017 | $1,812,000 | +38.3% | 42,050 | +0.5% | 0.14% | +39.4% |
Q1 2017 | $1,310,000 | +22.8% | 41,850 | -0.9% | 0.10% | +28.4% |
Q4 2016 | $1,067,000 | -5.6% | 42,250 | -7.5% | 0.08% | +12.5% |
Q3 2016 | $1,130,000 | +7.5% | 45,700 | -11.4% | 0.07% | +60.0% |
Q2 2016 | $1,051,000 | – | 51,600 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
S&T BANK/PA | 215,578 | $5,943 | 1.15% |
Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |